Hypertension

Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024

Retrieved on: 
Wednesday, March 13, 2024
Chronic kidney disease, CKD, Therapy, Hypertension

RADNOR, Pa., March 13, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced it will report its financial results from the fourth quarter and full year ended December 31, 2023, before the financial markets open on Thursday, March 21, 2024.

Key Points: 
  • RADNOR, Pa., March 13, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced it will report its financial results from the fourth quarter and full year ended December 31, 2023, before the financial markets open on Thursday, March 21, 2024.
  • Thursday, March 21st @ 8:30 a.m.
  • ET

Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue® SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting

Retrieved on: 
Wednesday, March 13, 2024
Blood pressure, CRT, Investigational device exemption, HOPE, Patient, Inflammation, Stroke, Gold, Restenosis, ISR, Medtronic, Beat (music), Trial of the century, Virtue, Sirolimus, Stent, Safety, Pharmacokinetics, SAB, Hypertension, Molecular mass, Food, Medical device

A second presentation featured recently reported clinical data on atrioventricular interval modulation (“AVIM”) therapy (also known as BackBeat CNT), an investigational therapy delivered via standard dual-chamber pacemakers designed to immediately, substantially and persistently lower blood pressure.

Key Points: 
  • A second presentation featured recently reported clinical data on atrioventricular interval modulation (“AVIM”) therapy (also known as BackBeat CNT), an investigational therapy delivered via standard dual-chamber pacemakers designed to immediately, substantially and persistently lower blood pressure.
  • The AVIM presentation also outlined the design of the currently enrolling BACKBEAT global pivotal study evaluating AVIM therapy in hypertensive pacemaker patients in collaboration with Medtronic.
  • Specifically, the presented PK data showed that:
    Molecular weight of Sostenocel remained unchanged prior to elimination, showing no evidence of in-vivo degradation.
  • AVIM therapy demonstrated:
    Consistent favorable hemodynamic effects using both conduction system, as well as traditional right ventricular lead placements.

 Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society

Retrieved on: 
Saturday, April 6, 2024
Biotechnology, Pharmaceutical, Health, Mental Health, BMY, Circulatory system, Head, Xerostomia, SIRS, Schizophrenia, Xanomeline, Dizziness, Glycated hemoglobin, Extrapyramidal symptoms, Weight gain, Patient, Syndrome, Constipation, Diarrhea, Bristol Myers Squibb, MD, Nature, Congress, Indigestion, Nausea, Prolactin, Safety, Vomiting, BMI, Schizophrenia International Research Society, Hypertension, Pharmaceutical industry

Bristol Myers Squibb (NYSE: BMY) today announced interim long-term safety, tolerability and metabolic outcomes data from its Phase 3 EMERGENT program evaluating KarXT (xanomeline-trospium) in adults with schizophrenia.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced interim long-term safety, tolerability and metabolic outcomes data from its Phase 3 EMERGENT program evaluating KarXT (xanomeline-trospium) in adults with schizophrenia.
  • “These long-term safety results and metabolic outcomes from the EMERGENT program are extremely encouraging, allowing us to further understand the tolerability profile of KarXT in people living with schizophrenia,” said Roland Chen , MD, senior vice president and head, Immunology, Cardiovascular and Neuroscience development, Bristol Myers Squibb.
  • In the pooled analysis, KarXT demonstrated a favorable impact on weight and long-term metabolic profile where most patients experienced stability or improvements on key metabolic parameters over 52 weeks of treatment.
  • In the long-term studies, KarXT was generally well-tolerated across 52 weeks of treatment, with a side effect profile consistent with prior trials of KarXT in schizophrenia.

Merck Foundation announced ‘‘Diabetes and Hypertension’’ Media Recognition Awards 2024 for Asian Countries

Retrieved on: 
Wednesday, April 3, 2024
Communications, Health, Diabetes, General Health, Other Communications, Media, Online, Hypertension, Merck, Subject, Prize money, Multimedia, Pharmaceutical industry

Merck Foundation ( www.merck-foundation.com ), the philanthropic arm of Merck KGaA Germany announced the call for applications for their Media Recognition ‘Diabetes & Hypertension’ Awards 2024 for the journalists from Asian Countries.

Key Points: 
  • Merck Foundation ( www.merck-foundation.com ), the philanthropic arm of Merck KGaA Germany announced the call for applications for their Media Recognition ‘Diabetes & Hypertension’ Awards 2024 for the journalists from Asian Countries.
  • View the full release here: https://www.businesswire.com/news/home/20240327714861/en/
    Merck Foundation announced ‘‘Diabetes and Hypertension’’ Media Recognition Awards 2024 for Asian Countries (Photo: Business Wire)
    The theme of the awards is to promote a healthy lifestyle and raise awareness about prevention and early detection of Diabetes and Hypertension.
  • Hence, I am inviting all media representatives from Asian Countries to participate for our Media Awards and share their most meaningful work that has helped raise awareness about diabetes and hypertension, and highlight the importance of leading a healthy lifestyle.”
    The awards are open to all the journalists in Asian Countries from Print, Online, Radio and Multimedia platforms.
  • Merck Foundation has also launched these awards for African and Latin American countries.

Purdue Pharma L.P. Awards Grant for Investigator-initiated Research to Examine Opioid Overdose Reversal Using Nalmefene HCl Injection

Retrieved on: 
Wednesday, March 27, 2024
Other Health, Research, General Health, Pharmaceutical, University, Education, Clinical Trials, Science, Biotechnology, FDA, Other Science, Health, Hypoventilation, Hypersensitivity, Nalmefene, IIR, Pulmonary edema, Doctor of Pharmacy, University of New Mexico, Safety, Tachycardia, Risk, Patient, Hydrogen chloride, Purdue Pharma, Naloxone, UNM, Emergency medicine, Ventricular tachycardia, Mortality, Buprenorphine, MD, Methadone, Emergency department, Ventricular fibrillation, Hypotension, Oxygen, HCI, ED, Hypertension, Recurrence, LAAM, Opioid overdose, Purdue University, Pharmaceutical industry

“We are enthusiastic about supporting research that can contribute to addressing the opioid overdose crisis.”

Key Points: 
  • “We are enthusiastic about supporting research that can contribute to addressing the opioid overdose crisis.”
    The prospective, randomized study, “Evaluation of Nalmefene HCl Injection for Recurrent Respiratory Depression After Suspected Acute Opioid Overdose in an Emergency Department,” will compare the efficacy and safety of nalmefene HCl injection to naloxone injection in the treatment of recurrent respiratory depression due to opioid overdose.
  • Nalmefene HCl injection is an opioid antagonist indicated for the complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids and in the management of known or suspected opioid overdose.
  • Nalmefene Hydrochloride injection is contraindicated in patients with a known hypersensitivity to the product.1 The Company distributes nalmefene HCl injection for no profit.
  • The study will be independently developed and carried out by UNM’s research team with Purdue Pharma providing only funding and nalmefene HCI injection.

Merck Foundation Announced "Diabetes and Hypertension" Media Recognition Awards 2024 for Latin American Countries

Retrieved on: 
Wednesday, April 3, 2024
Cardiology, Health, Media, Diabetes, Communications, Philanthropy, Consumer, Foundation, Online, Hypertension, Country, Merck, Subject, Prize money, Multimedia, Pharmaceutical industry

Merck Foundation ( www.merck-foundation.com ), the philanthropic arm of Merck KGaA Germany, announced the call for applications for their Media Recognition ‘Diabetes & Hypertension’ Awards 2024 for the journalists in Latin American Countries.

Key Points: 
  • Merck Foundation ( www.merck-foundation.com ), the philanthropic arm of Merck KGaA Germany, announced the call for applications for their Media Recognition ‘Diabetes & Hypertension’ Awards 2024 for the journalists in Latin American Countries.
  • View the full release here: https://www.businesswire.com/news/home/20240327222745/en/
    Merck Foundation Announced "Diabetes and Hypertension" Media Recognition Awards 2024 for Latin American Countries (Graphic: Business Wire)
    The theme of the awards is to promote a healthy lifestyle and raise awareness about prevention and early detection of Diabetes and Hypertension.
  • Senator, Dr. Rasha Kelej, CEO of Merck Foundation emphasized, “Media plays a critical role in enhancing awareness in the public on critical health issues.
  • Merck Foundation has also launched these awards for African and Asian countries.

Lyric Health Selects Reperio Health as Exclusive Partner for At-home Biometric Health Screenings

Retrieved on: 
Tuesday, March 26, 2024
Managed Care, Software, Mobile, Wireless, Telemedicine, Virtual Medicine, Biometrics, Apps, Applications, Technology, Medical Devices, Fitness & Nutrition, Biotechnology, Practice Management, Health, Diabetes, Risk, Tex, Stroke, FDA, Hypertension, Telehealth, Mobile phone

Reperio Health , the only provider of at-home and onsite comprehensive health screenings with instant results, announced today a new client relationship with Lyric Health , an award-winning virtual primary care company based in McKinney, Tex.

Key Points: 
  • Reperio Health , the only provider of at-home and onsite comprehensive health screenings with instant results, announced today a new client relationship with Lyric Health , an award-winning virtual primary care company based in McKinney, Tex.
  • Lyric Health will now offer its nationwide network access to Reperio’s at-home biometric health screening kits with instant results.
  • More than six million Lyric members will have access to Reperio’s patient-centric health screenings, empowering them with data and insights that can prevent health issues before they escalate into expensive and chronic conditions.
  • Added Naomi Levinthal, Chief Growth Officer of Reperio, “Lyric Health provides everything a member needs to navigate their health journey.

Teva UK and Closed Loop Medicine Announce Strategic Partnership to Advance Development of Personalised Medicines

Retrieved on: 
Tuesday, March 26, 2024
Software, Biotechnology, Pharmaceutical, Health, Medical Devices, Health Technology, Technology, Clinical Trials, Disease, Ulcerative colitis, Risk, Partnership, Patient, NHS, Mortality, Pivot, Pharmacotherapy, Investment, Clinical trial, Annual report, Inflammatory bowel disease, Teva, Therapy, Hypertension, Medicine, Pharmaceutical industry

Teva UK Limited and Closed Loop Medicine Ltd have announced a strategic partnership to advance the development of personalised medicines.

Key Points: 
  • Teva UK Limited and Closed Loop Medicine Ltd have announced a strategic partnership to advance the development of personalised medicines.
  • Under the agreement, Closed Loop Medicine – a leading TechBio company – and pharmaceutical company, Teva UK, will investigate opportunities to use Closed Loop Medicine’s proprietary software as a medical device (SaMD) technology platform which aims to advance the development of personalised medicines, improve drug efficacy and outcomes in patients with specific chronic disorders by combining dose-optimised drug therapy with digital care.
  • Dr Paul Goldsmith, Chief Medical Officer and Innovation Officer, Co-Founder and President of Closed Loop Medicine, said: “As clinicians, we know that dosing of drugs is a huge problem.
  • Being able to predict personalised dose levels could be transformational.”
    This strategic partnership harnesses Closed Loop Medicine’s proprietary SaMD and combines it with Teva’s pharmaceutical products creating the opportunity for digital companions to be prescribed alongside traditional therapeutics, enabling real-world data integration and improved effectiveness of innovative and known medicines.

Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Retrieved on: 
Tuesday, March 26, 2024
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Microangiopathic hemolytic anemia, Incidence, Headache, Patient, Thrombotic thrombocytopenic purpura, Constipation, Mortality, Head, TTP, Nausea, Toll, Heart, Safety, Itch, Thrombocytopenia, Hypertension, Pharmaceutical industry

Takeda ( TSE: 4502/NYSE:TAK ) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of ADZYNMA (apadamtase alfa /cinaxadamtase alfa) for the treatment of congenital thrombotic thrombocytopenic purpura (cTTP) for individuals 12 years of age and older.1 ADZYNMA is the first and only approved recombinant ADAMTS13 protein designed to address an unmet medical need in people with cTTP by replacing the deficient ADAMTS13 enzyme.

Key Points: 
  • Takeda ( TSE: 4502/NYSE:TAK ) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of ADZYNMA (apadamtase alfa /cinaxadamtase alfa) for the treatment of congenital thrombotic thrombocytopenic purpura (cTTP) for individuals 12 years of age and older.1 ADZYNMA is the first and only approved recombinant ADAMTS13 protein designed to address an unmet medical need in people with cTTP by replacing the deficient ADAMTS13 enzyme.
  • cTTP is an ultra-rare, chronic blood clotting disorder caused by a deficiency in the ADAMTS13 enzyme.2 It is associated with acute events and debilitating chronic symptoms or thrombotic thrombocytopenic purpura (TTP) manifestations, which can include thrombocytopenia, microangiopathic hemolytic anemia, headache and abdominal pain.2,3,4 When left untreated, acute TTP events have a mortality rate of >90%.2,4
    “The approval of ADZYNMA is an important milestone for people living with cTTP in Japan, who had limited treatment options and now have the first treatment option specifically approved to treat this ultra-rare condition,” said Yasushi Kajii, Head, R&D Japan Region at Takeda.
  • “Developing innovative treatments that make a difference in the lives of patients is at the heart of what we do.
  • In Period 3, the incidence of TEAEs was 2.8% (1/36) in this drug group: nausea and headache (1 subject each).6
    This approval does not result in any changes to Takeda’s consolidated forecast for the fiscal year ending March 31, 2024 (FY2023).

UniCare Health Plan of West Virginia First in the State to Earn NCQA Health Equity Accreditation Plus

Retrieved on: 
Thursday, March 21, 2024
Professional Services, DEI (Diversity, Equity and Inclusion), Health, Health Insurance, Social Services, General Health, Andrew Kohut, Disease, NCQA, Transport, Health equity, Diabetes, Mortality, Gender identity, Overalls, Medicaid, UniCare, Quality assurance, Language, Hypertension, Accreditation, National Committee, Nursing

UniCare Health Plan of West Virginia recently earned the National Committee for Quality Assurance (NCQA) Health Equity Accreditation Plus, a recognition of UniCare’s leadership in developing solutions to enhance access equitable, high-quality healthcare.

Key Points: 
  • UniCare Health Plan of West Virginia recently earned the National Committee for Quality Assurance (NCQA) Health Equity Accreditation Plus, a recognition of UniCare’s leadership in developing solutions to enhance access equitable, high-quality healthcare.
  • “NCQA’s Health Equity Accreditation Plus recognizes our unwavering dedication to eliminating health disparities and ensuring access to high-quality care for everyone,” said Tadd Haynes, President, UniCare Health Plan of West Virginia.
  • “This milestone positions UniCare at the forefront of advancing health equity through our innovative and impactful programs and personalized care to improve the whole health of our members.”
    NCQA Health Equity Accreditation Plus builds upon the Health Equity Accreditation designation UniCare received last year, when it was recognized among the first Medicaid plans in the nation to create a strategic framework that prioritizes health equity based on race, ethnicity, language, sexual orientation, and gender identity.
  • “Organizations earning the Health Equity Accreditation Plus like UniCare Health Plan of West Virginia are leading the way in bridging this gap, and NCQA salutes their commitment.”